Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is a Schedule IV controlled substance.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses may include other seizure types and anxiety disorders, though specific dosing for these indications is less established.
## Adult Dosing
* **Lennox-Gastaut Syndrome (Adjunctive):** Initiate at 5 mg twice daily. Increase by 5 mg to 10 mg every week as needed, up to a maximum of 20 mg twice daily.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (Adjunctive):**
* **2 to <10 years:** Initiate at 5 mg once daily. Increase by 2.5 mg to 5 mg every week as needed. Maximum daily dose depends on weight:
* 10 kg to <30 kg: 10 mg once daily.
* ≥30 kg: 20 mg once daily.
* **≥10 years:** Initiate at 5 mg twice daily. Increase by 5 mg to 10 mg every week as needed, up to a maximum of 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Caution is advised; no specific dosing adjustments are provided.
* **Renal Impairment:** Caution is advised; no specific dosing adjustments are provided.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, aggression, drooling, constipation, difficulty with coordination, rash, and behavioral problems. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, and withdrawal symptoms upon abrupt discontinuation.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Additive CNS depressant effects, increasing the risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam plasma concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam plasma concentrations.
* **Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin):** May decrease clobazam plasma concentrations.
* **Valproic Acid:** Coadministration may increase valproic acid concentrations and decrease clobazam concentrations.
## Monitoring
* Monitor for therapeutic response and signs of adverse effects, particularly somnolence, behavioral changes, and skin reactions.
* Monitor for signs of withdrawal if dose is reduced or discontinued.
* Monitor for efficacy in LGS and any potential for tolerance development.
## Clinical Pearls
* Clobazam should be tapered gradually upon discontinuation to avoid withdrawal symptoms.
* Be aware of the potential for increased suicidal thoughts or behavior in patients taking antiepileptic drugs.
* Clobazam is a Schedule IV controlled substance; follow appropriate prescribing and dispensing regulations.
* Dosage and titration for indications other than LGS are not well-established and should be approached with caution and careful patient selection.
***
*This information is intended for healthcare professionals. Always verify current prescribing information, including contraindications, warnings, and drug interactions, with the official product labeling and relevant clinical guidelines before making any treatment decisions.*
